Valuation: BioNTech SE

Market Cap 21.61B 24.32B 20.17B 18.38B 34.67B 2,338B 34.99B 244B 94.58B 1,195B 91.31B 89.33B 3,836B P/E 2026 *
-15.1x
P/E 2027 * -15.8x
Enterprise Value 10.24B 11.53B 9.56B 8.71B 16.43B 1,108B 16.58B 116B 44.82B 566B 43.27B 42.33B 1,818B EV / Sales 2026 *
5.67x
EV / Sales 2027 * 6.39x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-14.86%+2.41% - - 24.33B
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-2.32%+23.28%+77.03% 59.26B
+0.89%-0.77%+5.80%+32.89% 47.14B
-0.96%-4.50%+26.36%+33.18% 42.91B
+0.36%+0.81%+352.17%+689.61% 44.13B
-0.20%-0.77%+3.74%+100.60% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+2.33%-5.69%-27.28%+338.00% 23.71B
Average +0.26%-0.64%+52.89%+159.49% 43.6B
Weighted average by Cap. +0.36%-0.40%+58.02%+150.90%

Financials

2026 *2027 *
Net sales 1.81B 2.03B 1.69B 1.54B 2.9B 195B 2.93B 20.41B 7.91B 99.94B 7.64B 7.47B 321B 1.81B 2.04B 1.69B 1.54B 2.91B 196B 2.93B 20.46B 7.93B 100B 7.65B 7.49B 321B
Net income -1.38B -1.55B -1.28B -1.17B -2.21B -149B -2.23B -15.55B -6.03B -76.15B -5.82B -5.69B -244B -1.31B -1.47B -1.22B -1.11B -2.1B -142B -2.12B -14.8B -5.74B -72.48B -5.54B -5.42B -233B
Net Debt -11.37B -12.8B -10.61B -9.67B -18.24B -1,230B -18.41B -128B -49.76B -629B -48.04B -47B -2,018B -10.03B -11.29B -9.36B -8.53B -16.09B -1,085B -16.24B -113B -43.89B -555B -42.38B -41.46B -1,780B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-